Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

264.66 -13.36 (-4.81%)
Delayed Quote Updated: 2:52 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis (PRAX) Q2 2026 Earnings Call Transcript ↗
Two FDA applications advance as cash runway extends into 2028. 
Via The Motley Fool
Topics Earnings
Praxis Precision Medicines (NASDAQ:PRAX) Beats Q1 Estimates as FDA Accepts Two Key Drug Applications ↗
Via Chartmill
News headline image
Praxis Precision Medicines Q2 Earnings Call Highlights ↗
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and... 
Via MarketBeat
Topics Earnings
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Provides Vormatrigine Program Update
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases. 
Via The Motley Fool
Topics Regulatory Compliance Stocks
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases. 
Via The Motley Fool
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions. 
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Praxis (PRAX) Q1 2026 Earnings Call Transcript ↗
Praxis (PRAX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Praxis Precision Medicines Q1 Earnings Call Highlights ↗
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.